Ian Lorimer
Impact in
- Oncology top 2%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
Papers in
- Co-authors
- Ming‐Sound TsaoManijeh DaneshmandFrances A. ShepherdKeyue DingLesley SeymourSuzanne Kamel‐ReidJean-Claude CutzAkira Sakurada
- Journals
- Journal of Clinical Oncology (6 papers)Investigational New Drugs (1 paper)European Journal of Cancer (1 paper)Biochemical Journal (1 paper)Annals of Oncology (1 paper)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Ian Lorimer
28 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Oncology 1.6k
- Pulmonary and Respiratory Medicine 1.6k
- Cancer Research 454
- Otorhinolaryngology 57
- Molecular Biology 888
Countries citing papers authored by Ian Lorimer
This map shows the geographic impact of Ian Lorimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Lorimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Lorimer more than expected).
Fields of papers citing papers by Ian Lorimer
This network shows the impact of papers produced by Ian Lorimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Lorimer. The network helps show where Ian Lorimer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ian Lorimer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2019 | 4 | |
| 3 | 2018 | 2 | |
| 4 | 2016 | 5 | |
| 5 | 2013 | 31 | |
| 6 | 2012 | 3 | |
| 7 | 2011 | 99 | |
| 8 | 2011 | 49 | |
| 9 | 2010 | 2 | |
| 10 | 2010 | 58 | |
| 11 | Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome Hit paper breakdown → | 2005 | 1483 |
| 12 | 2005 | 35 | |
| 13 | 2005 | 16 | |
| 14 | 2001 | 11 | |
| 15 | 1999 | 8 | |
| 16 | Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. | 1999 | 49 |
| 17 | 1995 | 49 | |
| 18 | Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. | 1995 | 60 |
| 19 | 1994 | 19 | |
| 20 | Use of a ligand-screening procedure to study the interaction of S. cerevisiae alpha 2 repressor with its operator sequence. | 1992 | 4 |
About Ian Lorimer
Ian Lorimer is a scholar working on Aging, Genetics, Radiology, Nuclear Medicine and Imaging, Cancer Research and Pulmonary and Respiratory Medicine, having authored 28 papers that have together received 2.6k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (5 papers), Lung Cancer Treatments and Mutations (5 papers), Glioma Diagnosis and Treatment (4 papers), Radiomics and Machine Learning in Medical Imaging (3 papers), Toxin Mechanisms and Immunotoxins (3 papers), Cancer Genomics and Diagnostics (3 papers), Glycosylation and Glycoproteins Research (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Oncology (1.6k citations), Pulmonary and Respiratory Medicine (1.6k citations), Cancer Research (454 citations), Otorhinolaryngology (57 citations) and Molecular Biology (888 citations). Ian Lorimer has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Ming‐Sound Tsao, Manijeh Daneshmand, Frances A. Shepherd, Keyue Ding, Lesley Seymour, Suzanne Kamel‐Reid, Jean-Claude Cutz, Akira Sakurada, Jeremy A. Squire and Frank C. Richardson. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, European Journal of Cancer, Biochemical Journal and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.